


... .. C
... ..
... ..



温州康宁医院股份有限公司
Wenzhou Kangning Hospital Co., Ltd.

Company incorporated in the People's Republic of China

3. $\int_0^1 \int_0^1 \int_0^1 \frac{1}{1+x+y+z} dx dy dz = A \ln 2 + B \ln 3 + C \ln 4$

1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 840.

- ## Opinions of the Independent Investigation Committee and the Board on the Supplementary Report of the Independent Investigation

Figure 10 shows the results of the analysis of variance for the effect of the different factors on the response variables. The analysis of variance for the effect of the different factors on the response variables is presented in Table 10. The analysis of variance for the effect of the different factors on the response variables is presented in Table 10. The analysis of variance for the effect of the different factors on the response variables is presented in Table 10.

| Key Internal Control Issues | Rectifications |
|--|---|
| Entity-Level Review by COSO Framework | |
| <p>Control Environment – Conflict of Interest Reporting Mechanism</p> <p>As part of the internal control review, the audit team identified a weakness in the conflict of interest reporting mechanism. The current process requires employees to declare conflicts of interest annually, but it does not include a mechanism for reporting conflicts of interest that arise between annual declarations. This could result in conflicts of interest going unreported and potentially leading to conflicts of interest that are not managed appropriately.</p> <p>The audit team recommended that the entity implement a mechanism for reporting conflicts of interest that arise between annual declarations. This could be achieved by implementing a conflict of interest reporting form that employees can complete at any time during the year. The form should be reviewed by the appropriate authority and the results should be used to manage conflicts of interest appropriately.</p> <p>The entity has agreed to implement the recommended mechanism for reporting conflicts of interest that arise between annual declarations. The implementation is expected to be completed by the end of the year.</p> | <p>The audit team identified a weakness in the conflict of interest reporting mechanism. The current process requires employees to declare conflicts of interest annually, but it does not include a mechanism for reporting conflicts of interest that arise between annual declarations. This could result in conflicts of interest going unreported and potentially leading to conflicts of interest that are not managed appropriately.</p> <p>The audit team recommended that the entity implement a mechanism for reporting conflicts of interest that arise between annual declarations. This could be achieved by implementing a conflict of interest reporting form that employees can complete at any time during the year. The form should be reviewed by the appropriate authority and the results should be used to manage conflicts of interest appropriately.</p> <p>The entity has agreed to implement the recommended mechanism for reporting conflicts of interest that arise between annual declarations. The implementation is expected to be completed by the end of the year.</p> |

| Key Internal Control Issues | Rectifications |
|--|--|
| Entity-Level Review by COSO Framework | |
| <p>Control Environment – Succession Plan</p> <p>The Board of Directors has approved a succession plan for the CEO and the Chairman of the Board. The plan includes a process for identifying and developing potential successors, as well as a process for transitioning the company's leadership in the event of an unexpected departure. The plan also includes a process for ensuring that the company's operations are not disrupted in the event of a leadership transition.</p> | <p>The Board of Directors has approved a succession plan for the CEO and the Chairman of the Board. The plan includes a process for identifying and developing potential successors, as well as a process for transitioning the company's leadership in the event of an unexpected departure. The plan also includes a process for ensuring that the company's operations are not disrupted in the event of a leadership transition.</p> |
| <p>Risk Assessments – Anti-Money Laundering Mechanism</p> <p>The company has implemented a risk assessment process for identifying and assessing the risk of money laundering. The process includes a review of the company's operations and a review of the company's relationships with customers and suppliers. The company has also implemented a system for monitoring and reporting suspicious transactions.</p> | <p>The company has implemented a risk assessment process for identifying and assessing the risk of money laundering. The process includes a review of the company's operations and a review of the company's relationships with customers and suppliers. The company has also implemented a system for monitoring and reporting suspicious transactions.</p> |
| | |

B. 2022年12月31日, 本公司在A股、C股两个市场同时停牌, 且停牌期间, 本公司在A股、C股两个市场均未发生任何交易。2023年1月1日, 本公司在A股、C股两个市场同时复牌, 且复牌期间, 本公司在A股、C股两个市场均未发生任何交易。2023年1月14日, 本公司在A股、C股两个市场同时复牌, 且复牌期间, 本公司在A股、C股两个市场均未发生任何交易。

CONTINUED SUSPENSION OF TRADING

A. 2022年12月31日, 本公司在A股、C股两个市场同时停牌, 且停牌期间, 本公司在A股、C股两个市场均未发生任何交易。2023年1月1日, 本公司在A股、C股两个市场同时复牌, 且复牌期间, 本公司在A股、C股两个市场均未发生任何交易。2023年1月14日, 本公司在A股、C股两个市场同时复牌, 且复牌期间, 本公司在A股、C股两个市场均未发生任何交易。

Shareholders and potential investors of the Company are reminded to rationally deal with any information not officially released by the Company, and Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

B. 2022年12月31日, 本公司在A股、C股两个市场同时停牌, 且停牌期间, 本公司在A股、C股两个市场均未发生任何交易。2023年1月1日, 本公司在A股、C股两个市场同时复牌, 且复牌期间, 本公司在A股、C股两个市场均未发生任何交易。2023年1月14日, 本公司在A股、C股两个市场同时复牌, 且复牌期间, 本公司在A股、C股两个市场均未发生任何交易。

Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili
C. 2022年12月31日, 本公司在A股、C股两个市场同时停牌, 且停牌期间, 本公司在A股、C股两个市场均未发生任何交易。2023年1月1日, 本公司在A股、C股两个市场同时复牌, 且复牌期间, 本公司在A股、C股两个市场均未发生任何交易。2023年1月14日, 本公司在A股、C股两个市场同时复牌, 且复牌期间, 本公司在A股、C股两个市场均未发生任何交易。

2022年12月31日, 本公司在A股、C股两个市场同时停牌, 且停牌期间, 本公司在A股、C股两个市场均未发生任何交易。2023年1月1日, 本公司在A股、C股两个市场同时复牌, 且复牌期间, 本公司在A股、C股两个市场均未发生任何交易。2023年1月14日, 本公司在A股、C股两个市场同时复牌, 且复牌期间, 本公司在A股、C股两个市场均未发生任何交易。

A. 2022年12月31日, 本公司在A股、C股两个市场同时停牌, 且停牌期间, 本公司在A股、C股两个市场均未发生任何交易。2023年1月1日, 本公司在A股、C股两个市场同时复牌, 且复牌期间, 本公司在A股、C股两个市场均未发生任何交易。2023年1月14日, 本公司在A股、C股两个市场同时复牌, 且复牌期间, 本公司在A股、C股两个市场均未发生任何交易。